The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the seventh revision).
10.3760/cma.j.cn112138-20250808-00468
- Collective Name:Chinese Association Hematologists;Chinese Invasive Fungal Infection Working Group
- Publication Type:Journal Article
- MeSH:
Humans;
Invasive Fungal Infections/drug therapy*;
Hematologic Diseases/complications*;
Antifungal Agents/therapeutic use*;
Neoplasms/complications*;
Hematologic Neoplasms/complications*;
Mycoses/therapy*;
China
- From:
Chinese Journal of Internal Medicine
2025;64(12):1155-1168
- CountryChina
- Language:Chinese
-
Abstract:
In 2005, the Chinese Invasive Fungal Infection Working Group published the first guidelines for the diagnosis and treatment of invasive fungal disease (IFD) in patients with hematological disorders and cancers, with the sixth revision released in 2020. Numerous advances in the fields of hematological oncology treatment and the diagnosis and management of IFD have significantly influenced the corresponding strategies. Therefore, the Chinese Invasive Fungal Infection Working Group has reviewed key research advances from 2020 to 2024 and released the seventh revision of the Chinese guidelines. Major revisions include: changes in the epidemiology of IFD; evaluation of novel diagnostic methods (especially PCR and metagenomic next-generation sequencing); updated recommendations on therapeutic drug monitoring and in vitro drug sensitivity test; management of breakthrough IFD; targeted therapy of Pneumocystis jiroveci pneumonia and cryptococcosis; and updated recommendation on the duration of antifungal therapy.
